1 / 15

Neuromodulation Devices Market Analysis | Coherent Market Insights

Read here the market research report on u201cNeuromodulation Devices Marketu201d published by CMI team.

Download Presentation

Neuromodulation Devices Market Analysis | Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Coherent Market InsightS Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. Neuromodulation Devices Market Analysis (2020-2027) • Neuromodulation devices are implantable medical devices, which introduce therapeutic solutions to some chronic diseases through electric stimulation or medication. Based on the type of diseases they help to curb and the type of nerves they are associated with, neuromodulation devices are segmented into five major technologies, namely: spinal cord stimulation devices, deep brain stimulation devices, vagus nerve stimulation devices, sacral nerve stimulation devices and gastric electric stimulation devices. • The global neuromodulation devices market is estimated to account for US$ 9,298.7 Mn in terms of value in 2020 and is expected to reach US$ 24,768.8 Mn by the end of 2027.

  3. Global Neuromodulation Devices Market: Drivers • Increasing prevalence of neurological disorders is expected to propel growth of the global neuromodulation devices market over the forecast period. For instance, according to Alzheimer’s Association, around 5.8 million people in the U.S. aged 65 and older are living with Alzheimer's dementia in 2020. • Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.      • North America held dominant position in the global neuromodulation devices market in 2019, accounting for 58.6% share in terms of value, followed by Europe and Asia Pacific, respectively

  4. Figure 1. Global Neuromodulation Devices Market Share (%), by Value, by Region, 2019

  5. Global Neuromodulation Devices Market: Restraints • Side effects and risks associated with the use of neuromodulation devices are expected to hinder growth of the global neuromodulation devices market. Neuromodulation implanting surgery has certain side effects on the body such as allergy and hoarseness. The neuromodulation devices also carry some risks, owing to the electrical impulses generated by it. The device may cause damages to the nearby nerves and blood vessels, as in the case of a VNS pacemaker, it might cause damages to the vagus nerve, carotid artery and jugular veins. • Moreover, availability of alternate treatment procedures such as drugs and other surgeries (e.g. Pallidotomy) is also expected to limit growth of the market.

  6. Global Neuromodulation Devices Market: Opportunities  • Outsourcing of neuromodulation devices manufacturing is expected to offer lucrative growth opportunities for players in the market. Development of a neuromodulation device involves heavy manufacturing and marketing costs. Market players can opt for outsourcing for manufacturing neuromodulation devices. • Moreover, R&D in neuromodulation is also expected to aid in growth of the market. For instance, in April 2020, researchers from Shandong Jianzhu University, China, proposed an expanded digital hippocampal spurt neural network to simulate the mammalian cognitive system and to perform the neuroregulatory dynamics. .

  7. Figure 2. Global Neuromodulation Devices Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

  8. Market Trends/Key Takeaways • The market has witnessed some product recalls. In December 2019, LivaNova announced to recall its implantable vagus nerve stimulation SenTiva Generator System following reports of 14 reset errors that caused it to stop delivering therapy. • The market is also witnessing favorable reimbursement scenario in Europe. For instance, in February 2020, Axonics Modulation Technologies, Inc. received Status 1 reimbursement approval to the Axonics r-SNM System, a next generation rechargeable implantable neurostimulator, from the German Institute for the Hospital Remuneration System.

  9. Regulations • U.S. • Medical devices are categorized into one of three classes based on their degree of risk: Class I Class II, and Class III • Majority of neurological devices are classified as class II (moderate risk) or class III (high risk) devices. • Class II devices include neurostimulators, aneurysm clips, and blood clot retrievers • Class III devices include deep brain stimulators and medical devices for the treatment of brain tumors

  10. Global Neuromodulation Devices Market: Competitive Landscape • Major players operating in the global neuromodulation devices market include, Axonics Modulation Technologies, Inc., ShiraTronics, Inc., Bioness, Inc., LivaNova, Neuronetics, Inc., Medtronic plc, St. Jude Medical, Boston Scientific Corporation, Cyberonics, Nevro, Integer Holdings Corporation, and Uroplasty.

  11. Global Neuromodulation Devices Market: Key Developments • Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in March 2020, Neuronetics, Inc., a commercial stage medical technology company developing solutions for the treatment of psychiatric disorders, received Breakthrough Device Designation for its NeuroStar Advanced Therapy System for the treatment of bipolar depression, from the U.S. Food and Drug Administration. • Similarly, in January 2020, Bioness, Inc. received CE Mark approval for its StimRouterNeuromodulation System for the treatment of fecal incontinence, across Europe.

  12. Request sample copy here • Request pdf brochure here • Request Customization here • Talk to Analyst • Buy Now • Reference: • https://www.coherentmarketinsights.com/market-insight/neuromodulation-devices-market-3861

  13. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. • What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  14. Contact Us: • Mr. Shah • Coherent Market Insights Pvt. Ltd. • Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S. • Phone: +1-206-701-6702 • Email :sales@coherentmarketinsights.com

  15. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related